Brief: Axcella Announces Results From Phase 2a Placebo Controlled Clinical Trial For Long Covid Subjects

Axcella Health

02/08/2022 11:00

Aug 2 (Reuters) - Axcella Health Inc  AXLA.O :
    * AXCELLA ANNOUNCES RESULTS FROM PHASE 2A PLACEBO CONTROLLED
CLINICAL TRIAL FOR LONG COVID SUBJECTS
    * AXCELLA - SUBJECTS RECEIVING AXA1125 EXPERIENCED
CLINICALLY &
STATISTICALLY SIGNIFICANT IMPROVEMENT IN MENTAL AND PHYSICAL
FATIGUE SCORES VERSUS. PLACEBO
    * AXCELLA - NO SIGNIFICANT DIFFERENCE ON PRIMARY OUTCOME
MEASURE
OF PCRΤ FOLLOWING MODERATE EXERCISE BETWEEN SUBJECTS RECEIVING
AXA1125 AND PLACEBO
    * AXCELLA - AXA1125 WAS SAFE AND WELL TOLERATED WITH NO
SIGNIFICANT ADVERSE EVENTS REPORTED BY STUDY SUBJECTS
    * AXCELLA - THERE WAS A NOTABLE TREND TOWARD SIGNIFICANT
IMPROVEMENT IN SERUM LACTATE LEVELS AFTER A 6MWT IN AXA1125
SUBJECTS (P=0.0730)
    * AXCELLA - REGULATORY MEETINGS ARE PLANNED TO DISCUSS A
PATH TO
REGISTRATION TRIAL FOR AXA1125

Further company coverage:  AXLA.O 

 ((Reuters.Briefs@thomsonreuters.com;))